Review Article

ERA'S JOURNAL OF MEDICAL RESEARCH VOL.11 NO.1

DOI: 10.24041/ejmr2024.12

FECAL MICROBIOTA TRANSPLANTATION: A COMPREHENSIVE REVIEW

Silky Rai*, Subuhi Anwar, Mehnaz Khan****

Department of Oncopathology, Department of Pathology***

Tata Memorial Centre, Mahahmana Pandit Madan Mohan Malviya Cancer Centre and Homi Bhabha Cancer Hospital, Varanasi, U.P., India-221005*.

Era's Lucknow Medical College and Hospital, Era University, Sarfarazganj, Lucknow, U.P., India-226003**.

Received on : 25-05-2024
Accepted on : 18-06-2024

Address for correspondence

Dr. Silky Rai
Department of Oncopathology
Mahahmana Pandit Madan Mohan Malviya Cancer Centre, Varanasi-221005.
Email: drsilkyrai@gmail.com
Contact no: +91-

ABSTRACT

The goal of fecal microbiota transplantation (FMT), a therapeutic technique, is to restore the balance of gut microbiota by giving a recipient fecal material from a healthy donor. Modern clinical uses of FMT, which have their roots in ancient Chinese medicine, were well-known in the 1950s, especially for the treatment of severe Clostridium difficile infections (CDI). The importance of microbiota in human health is highlighted by the human microbiome, which is made up of billions of microorganisms that are essential for immunity, metabolism, and disease resistance. An imbalance in the makeup of the microbiota known as dysbiosis is linked to a number of illnesses, underscoring the potential therapeutic benefits of FMT. This review covers all the bases regarding FMT its history, current clinical uses in gastrointestinal disorders such as inflammatory bowel disease (IBD) and CDI, technological developments, regulatory issues, emerging clinical uses in neurological and metabolic disorders, and future directions for research. The review highlights FMT's effectiveness, safety concerns, and implications for healthcare strategy by synthesizing the body of existing literature. Research is still being done to improve procedures, investigate customized microbiota-based treatments, and expand the uses of FMT outside of gastrointestinal disorders. In order to advance FMT as a transformational therapy in precision medicine, cross-disciplinary collaboration is essential.

KEYWORDS: Theruputic, Dysbiosis, Fecal microbiota, Disorders.

INTRODUCTION

The goal of fecal microbiota transplantation (FMT), a therapeutic treatment, is to restore a disturbed gut microbiota and reduce symptoms of disease by transferring fecal material from a healthy donor to a recipient. Modern therapeutic uses of FMT gained popularity in the 1950s with successful treatments against severe instances of Clostridium difficile infection (CDI), a history that dates back to ancient Chinese medicine (1). Since then, FMT has developed into a potentially effective therapy option for a variety of gastrointestinal problems, and its application in treating ailments other than those of the gut is being investigated more and more.

The billions of bacteria that live in different parts of the human body, known as the microbiome, are essential to both promoting and preserving health. Specifically, the gut microbiota supports immune function regulation, host metabolism, and pathogen defense (Lloyd-Price et al., 2016 2). An imbalance in the composition of the microbiota known as dysbiosis has been linked to a number of illnesses, highlighting the vital role that microbial communities play in human physiology.

An extensive analysis of fecal microbiota transplantation is intended, including its historical evolution, present therapeutic uses, technological developments, regulatory issues, new clinical applications, and potential future research avenues. The goal of this review is to demonstrate the potential of FMT in clinical practice and its implications for future research and healthcare initiatives by synthesizing the available literature and analyzing major findings.

Fecal Microbiota Transplantation (FMT) Mechanisms

The Gut Microbiota's Function in Maintaining Health: A vital component of human health is the gut microbiota, which is made up of many bacterial species, fungi, viruses, and archaea. According to Lloyd-Price et al. (2016), it supports host metabolism, synthesizes vital vitamins, teaches the immune

system, and confers resistance against pathogen colonization. Maintaining gut homeostasis and general health depend on a balanced microbiome. (2)

Factors That Help FMT Restore the Equilibrium of Gut Microbiota

FMT restores microbial diversity and function in the gut by transplanting the microbiota of a healthy donor to a recipient. The following are the precise processes by which FMT achieves its therapeutic effects:

1. Microbial population Restoration: FMT restores the balance of the disturbed microbiota by introducing a varied population of microorganisms that can outcompete pathogens and restore beneficial species (3.
2. Improvement of Metabolic Function: The generation of short-chain fatty acids and the metabolism of bile acids are two metabolic processes that transplanted microbiota can improve and are related to host health (4).
3. Immunological Modulation: By controlling mucosal immunity and lowering inflammation, FMT can affect immunological responses, which is important in diseases such inflammatory bowel disease (5).
4. Resistance to Pathogens: Establishing a robust microbiome can boost defences against pathogens such as Clostridium difficile, lowering the likelihood of illness recurrence (6).

Encouraging the Effectiveness of FMT in the Treatment of Different Illnesses

FMT has been effective in treating a number of illnesses, mostly those linked to microbial imbalance and dysbiosis:

1. Clostridium difficile infection (CDI): In recurrent CDI cases that are resistant to antibiotic therapy, FMT is quite effective (>90% cure rates) (7).
2. Inflammatory Bowel Disease (IBD): Although findings from trials differ, FMT is promising in bringing patients with ulcerative colitis and Crohn's disease into remission and alleviating symptoms (8).
3. Metabolic Disorders: New study indicates that FMT may help improve insulin sensitivity and metabolic profiles in diseases including obesity and metabolic syndrome (9).
4. Neurological and Psychological health issues: Research on the potential involvement of gut-brain axis modulation in illnesses including depression and autism spectrum disorders, where FMT may be involved, is gaining traction (10).

Clinical Applications of FMT

CDI (Clostridium difficile infection) treatment: The most well-known application of FMT is the treatment of recurrent and resistant Clostridium difficile infection (CDI), which is frequently difficult to control with antibiotics alone. The etiology of CDI is dysbiosis of the gut microbiota, which facilitates the growth of Clostridium difficile and leads to severe diarrhoea and colitis. FMT suppresses and outcompetes Clostridium difficile by re-establishing a healthy microbial population (6). FMT is the recommended treatment for recurrent CDI since clinical trials and real-world research regularly indicate cure rates over 90% (1).

Potential Use in Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD)

1. Inflammatory Bowel Disease (IBD): FMT has demonstrated potential in bringing patients with Crohn's disease and ulcerative colitis, the two primary types of IBD, into remission and reducing their symptoms. Meta-analyses point to a positive impact, particularly in ulcerative colitis, despite the fact that outcomes have varied throughout research (8). The goal of on-going research is to find therapy response factors for IBD and optimize FMT regimens.
2. Irritable Bowel Syndrome (IBS): While less research has been done on IBS patients than on CDI and IBD patients, initial findings point to the potential benefits of FMT, especially for individuals with dysbiosis-related symptoms. There is continuing research in this patient population to assess long-term efficacy and clarify the mechanisms (11)

New Research on FMT Usage in Other Conditions

1. Obesity and Metabolic Syndrome: Preliminary research suggests that FMT from lean donors may enhance insulin sensitivity and metabolic parameters in those suffering from obesity and metabolic syndrome, pointing to a possible metabolic health function for gut microbiota regulation (9).
2. Autism Spectrum Disorders (ASD): The gut-brain axis theory postulates that the generation of neurotransmitters and immunological regulation by gut bacteria may have an impact on neurological diseases such as ASD. More thorough clinical trials are required to show efficacy and safety, however emerging research is investigating the impact of FMT on behavioral outcomes and symptoms of ASD (12).

In gastroenterology and beyond, functional movement therapy (FMT) is a fast developing discipline that has shown promise in treating irritable bowel syndrome, inflammatory bowel diseases, and neurological and metabolic problems. It has been proven effective in treating Crohn's disease (CDI). To optimize patient selection criteria, clarify mechanisms of action for a range of clinical diseases, and refine protocols, on-going research is crucial. Safety Considerations in FMT and Donor Screening

Choosing Appropriate Donors for FMT Is Essential: To guarantee the procedure's safety and effectiveness, it is essential to choose appropriate donors for FMT. Excellent general health, no gastrointestinal illnesses or infections, and a well-defined and stable gut microbiota composition are desirable qualities in donors (1). A few elements taken into account while choosing a donor are:

1. Health Screening: In order to rule out infectious diseases and other medical disorders that could endanger recipients, donors go through extensive health screenings that include a medical history, physical examination, and laboratory testing (such as blood and stool tests).
2. Microbiota Composition: Given that microbial diversity and composition can affect the results of FMT, donors should have a stable and diverse gut microbiota (3.
3. Behavioural Screening: To reduce potential exposure to pathogens or factors that could impact the makeup of the gut microbiota, lifestyle factors like food, medication usage, and travel history are also reviewed.

Screening Procedures to Reduce the Risk of Spreading Infections: Comprehensive screening measures are used during FMT to reduce the possibility of infection transmission:

1. Testing for Infectious Diseases: Using stool culture methods, molecular diagnostics, and serological testing, donors are examined for a variety of infectious agents, including as bacteria, viruses, parasites, and fungus (13).
2. Stool Testing: To ensure that stool samples are suitable for transplantation, a thorough study is performed on them to identify infections and evaluate the microbial composition (4).
3. Exclusion Criteria: Donors who have recently taken antibiotics, a history of gastrointestinal issues, have recently travelled to an area where an infection is endemic, or engages in high-risk activities for infectious diseases are not eligible.

Possible Long-Term Hazards and Issues Related to FMT

1. FMT has long-term problems and other hazards despite its effectiveness: Transmission of Infections: Tight screening lowers the danger, but there is still a chance that donors and recipients will become infected or colonized with opportunistic pathogens .
2. Gastrointestinal Symptoms: Following FMT, some recipients may have brief gastrointestinal symptoms, such as bloating, diarrhea, or discomfort in the abdomen. These symptoms usually go away on their own.
3. Immunological Risks: Research is still being done on the long-term consequences on host immunological responses and the interactions that occur between the recipient immune system and the transplanted microbiota (5).
4. Unknown Risks: More research is need to determine the long-term effects of modifying gut microbiota with FMT on immunological response, metabolic health, and susceptibility to chronic diseases (4)

FMT Regulation and Standardization

1. Provide the FMT Procedure Guidelines: While specific regulations may vary, FMT techniques are generally governed by a range of national and international standards. Important subjects that are frequently covered include
2. Donor screening: Strict guidelines are applied to select suitable donors to lower the risk of infection transmission. These guidelines include health evaluations, microbiota profiling, and the exclusion of high-risk behaviours (1).
3. Preparation of Fecal Material: To maintain microbial viability and composition, donor stool is prepared using standardized techniques such as homogenization, dilution, and filtering (4).
4. Administration Techniques: To optimize treatment effectiveness, recommendations for the route of administration (e.g., enema, capsules, and colonoscopy) are based on the features of the patient, the severity of the condition, and the clinical setting (1).

Particular Difficulties in Standardizing FMT Procedures

1. Microbial Composition and Diversity: It is difficult to establish a universal "standard" microbiota preparation that ensures consistent treatment outcomes due to donor stool

composition variability and the complexity of the gut microbiota (4).

2. Optimal Donor Selection: Variations in donor screening standards and techniques between facilities affect the safety and quality of stool preparations, which influences the results of FMT (1).
3. Protocol Variability: Treatment efficacy and safety vary between clinical settings due to healthcare professionals' differing protocols for stool preparation and administration techniques (4).

Clinical Practice Use of FMT

The regulation of FMT has changed over time to improve patient safety and effectiveness:

1. FDA Regulation in the US: FMT is governed by FDA regulations as an experimental novel medication (IND) for the management of recurrent Clostridium difficile infections that do not improve with conventional treatments. In order to reduce hazards, the FDA has released guidelines on donor screening, stool processing, and administration protocols (US FDA, 2020, 14).
2. Global Views: To guarantee patient safety and therapeutic efficacy, several nations have created particular laws or guidelines controlling the clinical use of FMT, with a strong emphasis on donor screening, procedural uniformity, and adverse event reporting (1).
3. Scientific Studies and Clinical Investigations: In order to influence future regulatory decisions, on-going clinical studies and research are intended to build evidence-based protocols, improve safety measures, and validate the therapeutic potential of FMT for diseases other than CDI (4)

Future Areas Research on FMT: As a therapeutic strategy, FMT is still developing, which has prompted research in a number of important areas, including:

1. Mechanistic Understanding: Deeper clarification of the ways in which the makeup and activities of the gut microbiota impact states of health and illness, as well as the part that certain microbial species or metabolites play in mediating therapeutic effects (3).
2. Protocol Optimization: To improve treatment efficacy and repeatability across a range of patient groups and clinical settings, standardized protocols for donor selection, stool preparation, and administration techniques have been developed (4).
3. Long-term Safety and Outcomes: Comprehensive follow-up studies are used to evaluate the long-term safety profile of FMT, taking into account potential concerns such as altered immune responses, metabolic consequences, and unintentional microbial colonization (5).
4. Investigation of New Indications: Using clinical trials and mechanistic investigations, FMT's potential to treat non-gastrointestinal ailments such metabolic disorders, neurological diseases, and autoimmune conditions is being investigated (9-10).

Possibility of Tailored Microbiota-Based Treatments: Personalized medicine in FMT refers to adjusting treatment plans according to host genetics, disease features, and individual microbiome profiles:

1. Profiling the Microbiota: The thorough analysis of individual microbiota compositions made possible by advances in metagenomics and bioinformatics facilitates tailored donor selection and treatment optimization (4).
2. Microbiota engineering: the creation of specified or synthetic microbial consortia that replicate the advantageous roles of a healthy gut microbiota, providing standardized and adaptable therapeutic alternatives (3).
3. Precision medicine approaches: Combining immunomodulators, probiotics, and dietary changes with microbiota-based medicines to provide individualized treatment plans and synergistic results (8).

CONCLUSION

FMT has shown potential in treating many gastrointestinal and systemic disorders and has become a game-changer for treating recurrent Clostridium difficile infections. Its potential to transform clinical practice by utilizing knowledge of the gut microbiota's function in health and disease is highlighted by current research. The field of personalized medicine and continuous breakthroughs in microbial science present great prospects to broaden the therapeutic applications of FMT, despite obstacles in regulatory frameworks and standardization. In the future, cooperation between scientists, medical professionals, and government agencies will be essential for improving procedures, setting security standards, and discovering new avenues for microbiota-based treatment. FMT has the potential to enhance patient outcomes and open the door for novel techniques in precision medicine by utilizing the power of the microbiome.

REFERENCES

1. Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66(4):569-580.
2. Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. Genome Med. 2016; 8(1): 51.
3. Allegretti JR, Fischer M, Sagi SV, et al. Fecal microbiota transplantation for Clostridioides difficile infection in a real-world setting: A single-center experience of 100 consecutive patients. Dig Dis Sci. 2021; 66(1): 142-149.
4. Ianiro G, Murri R, Sciumè GD, et al. Incidence of bloodstream infections, length of hospital stay, and survival in patients with recurrent Clostridioides difficile infection treated with fecal microbiota transplantation or antibiotics: A prospective cohort study. Ann Intern Med. 2019; 171(10): 695-702.
5. Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: A randomized trial. Ann Intern Med. 2016; 165(9): 609-616.
6. Kootte RS, Levin E, Salojärvi J, et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab. 2017; 26(4): 611-619.
7. Pamer EG. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science. 2016; 352(6285): 535-538.
8. Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: A randomised placebo-controlled trial. Lancet. 2017; 389(10075): 1218-1228.
9. Staley C, Kaiser T, Beura LK, et al. Stable engraftment of human microbiota into mice with a single oral gavage following antibiotic conditioning. Microbiome. 2017; 5(1): 87.
10. Johnsen PH, Hilpusch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol. 2018; 3(1): 17-24.
11. Kang DW, Adams JB, Gregory AC, et al. Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome. 2017; 5(1): 10.
12. Friedman-Moraco RJ, Mehta AK, Lyon GM, et al. Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients. Am J Transplant. 2020; 20(9): 2595-2601.
13. Gupta S, Allen-Vercoe E, Petrof EO. Fecal microbiota transplantation: in perspective. Therap Adv Gastroenterol. 2021; 14: 1756284821992947.
14. US Food and Drug Administration (FDA). Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies. Updated July 2020. Accessed June 24, 2024. FDA website

Orcid ID:

Silky Rai - https://orcid.org/

Subuhi Anwar - https://orcid.org/

Mehnaz Khan - https://orcid.org/

How to cite this article:

Rai S., Anwar S., Khan M. Accessory Breast Tumor In Male – Rare Case. Era J. Med. Res. 2024; 11(1): 71-75.